What is Conceivable Life Sciences?
Conceivable Life Sciences is at the forefront of reproductive technology, having developed the world's first AI-powered automated IVF lab. Its integrated platform, AURAs, redefines traditional IVF laboratory operations, which are largely manual and artisanal. AURAs delivers enhanced precision, superior quality, and increased scalability by automating critical functions such as dish preparation, sperm processing, egg discovery and preparation, ICSI, incubation, and vitrification/thawing. This technological leap aims to improve outcomes and accessibility in assisted reproductive treatments.
How much funding has Conceivable Life Sciences raised?
Conceivable Life Sciences has raised a total of $98.5M across 3 funding rounds:
Multiple Rounds
$98.5M
Series A (2025): $18M with participation from Acme Ventures, Muse Capital Management, and ARTIS Ventures
Private Equity (2025): $30.5M, investors not publicly disclosed
Series A (2025): $50M supported by Advance Venture Partners, Acme Capital, ARTIS Ventures, and Stride.VC
Key Investors in Conceivable Life Sciences
Advance Venture Partners
Advance Venture Partners is an evergreen venture capital firm that focuses on long-term investments in technology and tech-enabled companies, particularly in digital health, data platforms, and robotics, acting as a strategic partner for disruptive businesses.
ARTIS Ventures
ARTIS Ventures is a venture capital fund specializing in Tech Bio+Health, investing in data-driven life sciences companies that leverage AI and engineering for personalized therapeutics and efficient drug discovery, aiming for a significant global impact in health and wellness.
Stride.VC
Stride.VC is a London-based seed-stage tech fund that provides meaningful investments and hands-on support to passionate entrepreneurs, prioritizing prototypes and nurturing early-stage companies.
What's next for Conceivable Life Sciences?
With the infusion of $50M in a major strategic investment and a cumulative total of $98.5M, Conceivable Life Sciences is poised for significant expansion. The company's focus on AI-driven automation in IVF labs positions it to capture a substantial share of the growing fertility market. Future developments will likely involve scaling its proprietary AURAs platform, expanding its service offerings, and potentially forging strategic partnerships within the broader healthcare and biotechnology industries. This substantial backing indicates strong investor confidence in Conceivable's disruptive technology and its potential to reshape the future of fertility treatments.
See full Conceivable Life Sciences company page
